The increasing role of health economic evaluations in drug development

Drug Development Research

Volumn 71, Issue 8, 2010, Pages 457-462

  Annemans, Lieven ^a,b   Cleemput, Irina ^c   Simoens, Steven ^d   Arickx, Francis ^e   Hulstaert, Frank ^c   Bogaert, Marc ^f  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e NIHDI   (Belgium)

^f Belgian Centre for Pharmaceutical Information   (Belgium)

Author keywords

budget impact analysis; cost effectiveness; health technology assessment; relative effectiveness

Indexed keywords

BUDGET; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG DEVELOPMENT; DRUG INDUSTRY; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; FUNDING; HEALTH CARE COST; HEALTH CARE POLICY; MARKETING; MEDICAL ETHICS; MEDICAL PRACTICE; QUALITY OF LIFE; REVIEW; SOCIETY;

EID: 78651104737     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20420     Document Type: Review

References (13)

1. Annemans L,. 2008. Health economics for non-economists: an introduction to the concepts, methods and pitfalls of health economic evaluations. Ghent, The Netherlands: Academia Press.
2. Annemans L, et al. 2010. A call to make valuable innovative medicines accessible in the European Union. Background report for the ministerial conference, September 23-24, 2010.
3. Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ,. 2009. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 302: 1437-1443.
4. Cohen, et al. 2008. Role of budget imact in drug reimbursement decisions. Health Polit Policy Law 33: 225-247.
5. Drummond MF, Schwartz JS, Jönsson B, Luce BR, Neumann PJ, Siebert U, Sullivan SD,. 2008. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care 24: 244-258.
6. Jacobzone S,. 2003. Introduction to the ageing-related diseases project. In a disease-based comparison of health systems what is best at what cost? OECD.
7. Mauskopf, et al. 2007. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practicesa-budget impact analysis. Value Health 10: 336-347.
8. Mertens R,. 2010. Measuring innovation. Lecture at the High Level Conference "Innovation and Solidarity". September 23-24 Brussels ().
9. NICE..
10. Senate of the USA. Amendment 2786. Comparative Effectiveness Research. 2009.
11. Sorenson C, Drummond MF, Kanavos P,. 2008. Ensuring value for money in health care: the role of HTA in the European Union, European Observatory on Health Systems and Policies. Copenhagen: WHO.
12. Schokkaert E,. 2010. Solidarity, ethics and innovation. Keynote lecture at the High Level Conference "Innovation and Solidarity". September 23-24 Brussels ().
13. Weinstein MC, Skinner JA,. 2010., Comparative effectiveness and health care spendinga-implications for reform,. N Engl J Med 362: 460-465.